XML 16 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Label Element Value
Risk/Return: rr_RiskReturnAbstract  
Registrant Name dei_EntityRegistrantName PRUDENTIAL SECTOR FUNDS, INC.
Prospectus Date rr_ProspectusDate Jan. 30, 2020
PGIM Jennison Health Sciences Fund  
Risk/Return: rr_RiskReturnAbstract  
Risk/Return [Heading] rr_RiskReturnHeading FUND SUMMARY IMPORTANT NOTE: Effective February 24, 2020, the Fund will be re-opened to investment by new investors in Class A, C, R, Z and R6 shares of the Fund. From June 29, 2012 to February 24, 2020, the Fund is generally closed to new investors. Please see “More About the Fund’s Investment Strategies, Investments and Risks” in the Prospectus for details.
Objective [Heading] rr_ObjectiveHeading INVESTMENT OBJECTIVE
Objective, Primary [Text Block] rr_ObjectivePrimaryTextBlock The investment objective of the Fund is long-term capital appreciation.
Expense [Heading] rr_ExpenseHeading FUND FEES AND EXPENSES
Expense Narrative [Text Block] rr_ExpenseNarrativeTextBlock The tables below describe the sales charges, fees and expenses that you may pay if you buy and hold shares of the Fund. You may be required to pay commissions to a broker for transactions in Class Z shares, which are not reflected in the table or the example below. You may qualify for sales charge discounts if you and an eligible group of related investors purchase, or agree to purchase in the future, $25,000 or more in shares of the Fund or other funds in the PGIM Funds family. More information about these discounts as well as other waivers or discounts is available from your financial professional and is explained in Reducing or Waiving Class A's and Class C’s Sales Charges on page 23 of the Fund's Prospectus, Appendix A: Waivers and Discounts Available From Certain Financial Intermediaries on page 47 of the Fund's Prospectus and in Rights of Accumulation on page 65 of the Fund's Statement of Additional Information (SAI).
Shareholder Fees Caption [Text] rr_ShareholderFeesCaption Shareholder Fees (fees paid directly from your investment)
Operating Expenses Caption [Text] rr_OperatingExpensesCaption Annual Fund Operating Expenses (expenses that you pay each year as a percentage of the value of your investment)
Fee Waiver or Reimbursement over Assets, Date of Termination rr_FeeWaiverOrReimbursementOverAssetsDateOfTermination March 31, 2021
Portfolio Turnover [Heading] rr_PortfolioTurnoverHeading Portfolio Turnover.
Portfolio Turnover [Text Block] rr_PortfolioTurnoverTextBlock The Fund pays transaction costs, such as commissions, when it buys and sells securities (or “turns over” its portfolio). A higher portfolio turnover rate may indicate higher transaction costs and may result in higher taxes when Fund shares are held in a taxable account. These costs, which are not reflected in annual fund operating expenses or in the example, affect the Fund's performance. During the Fund's most recent fiscal year, the Fund's portfolio turnover rate was 30% of the average value of its portfolio.
Portfolio Turnover, Rate rr_PortfolioTurnoverRate 30.00%
Expense Breakpoint Discounts [Text] rr_ExpenseBreakpointDiscounts You may qualify for sales charge discounts if you and an eligible group of related investors purchase, or agree to purchase in the future, $25,000 or more in shares of the Fund or other funds in the PGIM Funds family.
Expense Breakpoint, Minimum Investment Required [Amount] rr_ExpenseBreakpointMinimumInvestmentRequiredAmount $ 25,000
Expense Example [Heading] rr_ExpenseExampleHeading Example.
Expense Example Narrative [Text Block] rr_ExpenseExampleNarrativeTextBlock The following hypothetical example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. It assumes that you invest $10,000 in the Fund for the time periods indicated and then, except as indicated, redeem all your shares at the end of those periods. It assumes a 5% return on your investment each year, that the Fund's operating expenses remain the same (except that fee waivers or reimbursements, if any, are only reflected in the 1-Year figures) and that all dividends and distributions are reinvested. Your actual costs may be higher or lower.
Expense Example by, Year, Caption [Text] rr_ExpenseExampleByYearCaption If Shares Are Redeemed
Expense Example, No Redemption, By Year, Caption [Text] rr_ExpenseExampleNoRedemptionByYearCaption If Shares Are Not Redeemed
Strategy [Heading] rr_StrategyHeading INVESTMENTS, RISKS AND PERFORMANCE Principal Investment Strategies.
Strategy Narrative [Text Block] rr_StrategyNarrativeTextBlock The Fund seeks investments whose prices will increase over time. The Fund normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector. The group of industries in which the Fund concentrates its investments is known as its “sector”. The term “investable assets” refers to the Fund's net assets plus any borrowings for investment purposes. The Fund's investable assets will be less than its total assets to the extent that it has borrowed money for non-investment purposes, such as to meet anticipated redemptions.

The Fund invests in securities of issuers among a number of different countries throughout the world, one of which is the United States. The Fund has no limit on the amount of assets that must be invested in each country. However, the Fund’s investments in the securities of non-US issuers, which we refer to as “foreign securities” and includes stocks and other equity-related securities, is limited to 35% of the Fund's total assets.

The Fund holds those equity and equity-related securities in which the portfolio managers have a high level of conviction for outperformance in the intermediate and long term and believe have limited downside potential in the short term. Equity and equity-related securities in which the Fund primarily invests are common stocks, nonconvertible preferred stocks and convertible securities. The portfolio managers use fundamental and quantitative analyses to select individual securities, and they may invest more than 5% of the Fund's assets in any one issuer. The Fund participates in the initial public offering (IPO) market.

The subadviser considers selling or reducing a stock position when, in the opinion of the subadviser, the stock has experienced a fundamental disappointment in earnings; the stock has experienced adverse price movement; the stock has reached an intermediate-term price objective and its outlook no longer seems sufficiently promising; or a relatively more attractive stock emerges.
Strategy Portfolio Concentration [Text] rr_StrategyPortfolioConcentration The Fund normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector.
Risk [Heading] rr_RiskHeading Principal Risks.
Risk Narrative [Text Block] rr_RiskNarrativeTextBlock All investments have risks to some degree. An investment in the Fund is not guaranteed to achieve its investment objective; is not a deposit with a bank; is not insured, endorsed or guaranteed by the Federal Deposit Insurance Corporation or any other government agency; and is subject to investment risks, including possible loss of your investment. The order of the below risk factors does not indicate the significance of any particular risk factor.

Currency Risk. The Fund's net asset value could decline as a result of changes in exchange rates, which could adversely affect the Fund’s investments in currencies, or in securities that trade in, and receive revenues related to, currencies, or in derivatives that provide exposure to currencies. Certain foreign countries may impose restrictions on the ability of issuers of foreign securities to make payment of principal and interest or dividends to investors located outside the country, due to blockage of foreign currency exchanges or otherwise.

Economic and Market Events Risk. Events in the US and global financial markets, including actions taken by the US Federal Reserve or foreign central banks to stimulate or stabilize economic growth, may at times result in unusually high market volatility, which could negatively impact performance. Relatively reduced liquidity in credit and fixed income markets could adversely affect issuers worldwide.

Equity and Equity-Related Securities Risk. The value of a particular security could go down and you could lose money. In addition to an individual security losing value, the value of the equity markets or a sector in which the Fund invests could go down. The Fund's holdings can vary significantly from broad market indexes and the performance of the Fund can deviate from the performance of these indexes. Different parts of a market can react differently to adverse issuer, market, regulatory, political and economic developments.

Foreign Securities Risk. The Fund’s investments in securities of foreign issuers or issuers with significant exposure to foreign markets involve additional risk. The securities of such issuers may trade in markets that are less liquid, less regulated and more volatile than US markets. The value of the Fund’s investments may decline because of factors affecting the particular issuer as well as foreign markets and issuers generally, such as unfavorable government actions, and political or financial instability. Lack of information may also affect the value of these securities.

Growth Style Risk. The Fund's growth style may subject the Fund to above-average fluctuations as a result of seeking higher than average capital growth. Historically, growth stocks have performed best during later stages of economic expansion and value stocks have performed best during periods of economic recovery. Since the Fund follows a growth investment style, there is the risk that the growth investment style may be out of favor for a period of time. At times when the style is out of favor, the Fund may underperform the market in general, its benchmark and other mutual funds.

Health Sciences Sector Risk. Investments in health sciences companies are subject to a number of risks, including the adverse impact of legislative actions and government regulations. These actions and regulations can affect the approval process for patents, medical devices and drugs, the funding of research and medical care programs, and the operation and licensing of facilities and personnel. Biotechnology and related companies are affected by patent considerations, intense competition, rapid technology change and obsolescence, and regulatory requirements of various federal and state agencies. In addition, some of these companies are relatively small and have thinly traded securities, may not yet offer products or may offer a single product, and may have persistent losses during a new product’s transition from development to production, or erratic revenue patterns. The stock prices of these companies are very volatile, particularly when their products are up for regulatory approval and/or under regulatory scrutiny.

Increase in Expenses Risk. Your actual cost of investing in the Fund may be higher than the expenses shown in the expense table for a variety of reasons. For example, expense ratios may be higher than those shown if average net assets decrease. Net assets are more likely to decrease and Fund expense ratios are more likely to increase when markets are volatile. Active and frequent trading of Fund securities can increase expenses.

Initial Public Offerings Risk. The volume of IPOs and the levels at which the newly issued stocks trade in the secondary market are affected by the performance of the stock market overall. If IPOs are brought to the market, availability may be limited and if the Fund desires to acquire shares in such an offering, it may not be able to buy any shares at the offering price, or if it is able to buy shares, it may not be able to buy as many shares at the offering price as it would like. The prices of securities involved in IPOs are often subject to greater and more unpredictable price changes than more established stocks. Such unpredictability can have a dramatic impact on the Fund's performance (higher or lower) and any assumptions by investors based on the affected performance may be unwarranted. In addition, as Fund assets grow, the impact of IPO investments on performance will decline, which could reduce total returns.

Management Risk. The value of your investment may decrease if judgments by the subadviser about the attractiveness, value or market trends affecting a particular security, industry or sector or about market movements are incorrect.

Market Capitalization Risk. The Fund may invest in companies of any market capitalization. Generally, the stock prices of small- and mid-cap companies are less stable than the prices of large-cap stocks and may present greater risks. Large capitalization companies as a group could fall out of favor with the market, causing the Fund to underperform compared to investments that focus on smaller capitalized companies.

Market Risk. Securities markets may be volatile and the market prices of the Fund’s securities may decline. Securities fluctuate in price based on changes in an issuer’s financial condition and overall market and economic conditions. If the market prices of the securities owned by the Fund fall, the value of your investment in the Fund will decline.

Non-Diversification Risk. The Fund is non-diversified for purposes of the Investment Company Act of 1940 (1940 Act). This means that the Fund may invest a greater percentage of its assets in the securities of a single company or other issuer than a diversified fund. Investing in a non-diversified fund involves greater risk than investing in a diversified fund because a loss resulting from the decline in value of any one security may represent a greater portion of the total assets of a non-diversified fund.
Risk Lose Money [Text] rr_RiskLoseMoney and is subject to investment risks, including possible loss of your investment.
Risk Not Insured Depository Institution [Text] rr_RiskNotInsuredDepositoryInstitution An investment in the Fund is not guaranteed to achieve its investment objective; is not a deposit with a bank; is not insured, endorsed or guaranteed by the Federal Deposit Insurance Corporation or any other government agency;
Risk Nondiversified Status [Text] rr_RiskNondiversifiedStatus Non-Diversification Risk. The Fund is non-diversified for purposes of the Investment Company Act of 1940 (1940 Act). This means that the Fund may invest a greater percentage of its assets in the securities of a single company or other issuer than a diversified fund. Investing in a non-diversified fund involves greater risk than investing in a diversified fund because a loss resulting from the decline in value of any one security may represent a greater portion of the total assets of a non-diversified fund.
Bar Chart and Performance Table [Heading] rr_BarChartAndPerformanceTableHeading Performance.
Performance Narrative [Text Block] rr_PerformanceNarrativeTextBlock The following bar chart shows the Fund's performance for Class Z shares for each full calendar year of operations or for the last 10 calendar years, whichever is shorter. The following table shows the Fund's average annual returns and also compares the Fund’s performance with the average annual total returns of an index or other benchmark. The bar chart and table demonstrate the risk of investing in the Fund by showing how returns can change from year to year.

Past performance (before and after taxes) does not mean that the Fund will achieve similar results in the future. Updated Fund performance information is available online at www.pgiminvestments.com.
Performance Information Illustrates Variability of Returns [Text] rr_PerformanceInformationIllustratesVariabilityOfReturns The following table shows the Fund's average annual returns and also compares the Fund’s performance with the average annual total returns of an index or other benchmark. The bar chart and table demonstrate the risk of investing in the Fund by showing how returns can change from year to year.
Performance Availability Website Address [Text] rr_PerformanceAvailabilityWebSiteAddress www.pgiminvestments.com
Performance Past Does Not Indicate Future [Text] rr_PerformancePastDoesNotIndicateFuture Past performance (before and after taxes) does not mean that the Fund will achieve similar results in the future.
Bar Chart [Heading] rr_BarChartHeading Annual Total Returns (Class Z Shares)
Bar Chart Closing [Text Block] rr_BarChartClosingTextBlock
Best Quarter:Worst Quarter:
18.22%4th Quarter 2019-20.47%4th Quarter 2018
Performance Table Heading rr_PerformanceTableHeading Average Annual Total Returns % (including sales charges) (as of 12-31-19)
Performance Table Uses Highest Federal Rate rr_PerformanceTableUsesHighestFederalRate After-tax returns are calculated using the highest historical individual federal marginal income tax rates and do not reflect the impact of state and local taxes.
Performance Table Not Relevant to Tax Deferred rr_PerformanceTableNotRelevantToTaxDeferred After-tax returns shown are not relevant to investors who hold their Fund shares through tax-deferred arrangements, such as 401(k) plans or individual retirement accounts.
Performance Table One Class of after Tax Shown [Text] rr_PerformanceTableOneClassOfAfterTaxShown After-tax returns are shown only for Class Z shares. After-tax returns for other classes will vary due to differing sales charges and expenses.
Performance Table Narrative rr_PerformanceTableNarrativeTextBlock ° After-tax returns are calculated using the highest historical individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on an investor's tax situation and may differ from those shown. After-tax returns shown are not relevant to investors who hold their Fund shares through tax-deferred arrangements, such as 401(k) plans or individual retirement accounts. After-tax returns are shown only for Class Z shares. After-tax returns for other classes will vary due to differing sales charges and expenses.
PGIM Jennison Health Sciences Fund | Class A  
Risk/Return: rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice 5.50%
Maximum deferred sales charge (load)(as a percentage of the lower of the original purchase price or the net asset value at redemption) rr_MaximumDeferredSalesChargeOverOther 1.00%
Maximum sales charge (load) imposed on reinvested dividends and other distributions rr_MaximumSalesChargeOnReinvestedDividendsAndDistributionsOverOther none
Redemption fee rr_RedemptionFeeOverRedemption none
Exchange fee rr_ExchangeFeeOverRedemption none
Maximum account fee (accounts under $10,000) rr_MaximumAccountFee $ 15
Management fees rr_ManagementFeesOverAssets 0.72%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 0.30%
Other expenses rr_OtherExpensesOverAssets 0.13%
Total annual Fund operating expenses rr_ExpensesOverAssets 1.15%
Fee waiver and/or expense reimbursement rr_FeeWaiverOrReimbursementOverAssets none
Total annual Fund operating expenses after fee waiver and/or expense reimbursement rr_NetExpensesOverAssets 1.15% [1],[2]
1 Year rr_ExpenseExampleYear01 $ 661
3 Years rr_ExpenseExampleYear03 895
5 Years rr_ExpenseExampleYear05 1,148
10 Years rr_ExpenseExampleYear10 1,871
1 Year rr_ExpenseExampleNoRedemptionYear01 661
3 Years rr_ExpenseExampleNoRedemptionYear03 895
5 Years rr_ExpenseExampleNoRedemptionYear05 1,148
10 Years rr_ExpenseExampleNoRedemptionYear10 $ 1,871
One Year rr_AverageAnnualReturnYear01 11.74%
Five Years rr_AverageAnnualReturnYear05 4.79%
Ten Years rr_AverageAnnualReturnYear10 16.11%
Since Inception rr_AverageAnnualReturnSinceInception
PGIM Jennison Health Sciences Fund | Class B  
Risk/Return: rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum deferred sales charge (load)(as a percentage of the lower of the original purchase price or the net asset value at redemption) rr_MaximumDeferredSalesChargeOverOther 5.00%
Maximum sales charge (load) imposed on reinvested dividends and other distributions rr_MaximumSalesChargeOnReinvestedDividendsAndDistributionsOverOther none
Redemption fee rr_RedemptionFeeOverRedemption none
Exchange fee rr_ExchangeFeeOverRedemption none
Maximum account fee (accounts under $10,000) rr_MaximumAccountFee $ 15
Management fees rr_ManagementFeesOverAssets 0.72%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 1.00%
Other expenses rr_OtherExpensesOverAssets 0.50%
Total annual Fund operating expenses rr_ExpensesOverAssets 2.22%
Fee waiver and/or expense reimbursement rr_FeeWaiverOrReimbursementOverAssets none
Total annual Fund operating expenses after fee waiver and/or expense reimbursement rr_NetExpensesOverAssets 2.22% [1],[2]
1 Year rr_ExpenseExampleYear01 $ 725
3 Years rr_ExpenseExampleYear03 994
5 Years rr_ExpenseExampleYear05 1,290
10 Years rr_ExpenseExampleYear10 2,156
1 Year rr_ExpenseExampleNoRedemptionYear01 225
3 Years rr_ExpenseExampleNoRedemptionYear03 694
5 Years rr_ExpenseExampleNoRedemptionYear05 1,190
10 Years rr_ExpenseExampleNoRedemptionYear10 $ 2,156
One Year rr_AverageAnnualReturnYear01 11.82%
Five Years rr_AverageAnnualReturnYear05 4.98%
Ten Years rr_AverageAnnualReturnYear10 15.89%
Since Inception rr_AverageAnnualReturnSinceInception
PGIM Jennison Health Sciences Fund | Class C  
Risk/Return: rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum deferred sales charge (load)(as a percentage of the lower of the original purchase price or the net asset value at redemption) rr_MaximumDeferredSalesChargeOverOther 1.00%
Maximum sales charge (load) imposed on reinvested dividends and other distributions rr_MaximumSalesChargeOnReinvestedDividendsAndDistributionsOverOther none
Redemption fee rr_RedemptionFeeOverRedemption none
Exchange fee rr_ExchangeFeeOverRedemption none
Maximum account fee (accounts under $10,000) rr_MaximumAccountFee $ 15
Management fees rr_ManagementFeesOverAssets 0.72%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 1.00%
Other expenses rr_OtherExpensesOverAssets 0.11%
Total annual Fund operating expenses rr_ExpensesOverAssets 1.83%
Fee waiver and/or expense reimbursement rr_FeeWaiverOrReimbursementOverAssets none
Total annual Fund operating expenses after fee waiver and/or expense reimbursement rr_NetExpensesOverAssets 1.83% [1],[2]
1 Year rr_ExpenseExampleYear01 $ 286
3 Years rr_ExpenseExampleYear03 576
5 Years rr_ExpenseExampleYear05 990
10 Years rr_ExpenseExampleYear10 2,148
1 Year rr_ExpenseExampleNoRedemptionYear01 186
3 Years rr_ExpenseExampleNoRedemptionYear03 576
5 Years rr_ExpenseExampleNoRedemptionYear05 990
10 Years rr_ExpenseExampleNoRedemptionYear10 $ 2,148
One Year rr_AverageAnnualReturnYear01 16.45%
Five Years rr_AverageAnnualReturnYear05 5.26%
Ten Years rr_AverageAnnualReturnYear10 15.96%
Since Inception rr_AverageAnnualReturnSinceInception
PGIM Jennison Health Sciences Fund | Class R  
Risk/Return: rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum deferred sales charge (load)(as a percentage of the lower of the original purchase price or the net asset value at redemption) rr_MaximumDeferredSalesChargeOverOther none
Maximum sales charge (load) imposed on reinvested dividends and other distributions rr_MaximumSalesChargeOnReinvestedDividendsAndDistributionsOverOther none
Redemption fee rr_RedemptionFeeOverRedemption none
Exchange fee rr_ExchangeFeeOverRedemption none
Maximum account fee (accounts under $10,000) rr_MaximumAccountFee none
Management fees rr_ManagementFeesOverAssets 0.72%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 0.75%
Other expenses rr_OtherExpensesOverAssets 0.38%
Total annual Fund operating expenses rr_ExpensesOverAssets 1.85%
Fee waiver and/or expense reimbursement rr_FeeWaiverOrReimbursementOverAssets (0.25%)
Total annual Fund operating expenses after fee waiver and/or expense reimbursement rr_NetExpensesOverAssets 1.60% [1],[2]
1 Year rr_ExpenseExampleYear01 $ 163
3 Years rr_ExpenseExampleYear03 557
5 Years rr_ExpenseExampleYear05 977
10 Years rr_ExpenseExampleYear10 2,149
1 Year rr_ExpenseExampleNoRedemptionYear01 163
3 Years rr_ExpenseExampleNoRedemptionYear03 557
5 Years rr_ExpenseExampleNoRedemptionYear05 977
10 Years rr_ExpenseExampleNoRedemptionYear10 $ 2,149
One Year rr_AverageAnnualReturnYear01 17.71%
Five Years rr_AverageAnnualReturnYear05 5.69%
Ten Years rr_AverageAnnualReturnYear10
Since Inception rr_AverageAnnualReturnSinceInception 15.34%
Inception Date rr_AverageAnnualReturnInceptionDate Feb. 03, 2012
PGIM Jennison Health Sciences Fund | Class Z  
Risk/Return: rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum deferred sales charge (load)(as a percentage of the lower of the original purchase price or the net asset value at redemption) rr_MaximumDeferredSalesChargeOverOther none
Maximum sales charge (load) imposed on reinvested dividends and other distributions rr_MaximumSalesChargeOnReinvestedDividendsAndDistributionsOverOther none
Redemption fee rr_RedemptionFeeOverRedemption none
Exchange fee rr_ExchangeFeeOverRedemption none
Maximum account fee (accounts under $10,000) rr_MaximumAccountFee none [3]
Management fees rr_ManagementFeesOverAssets 0.72%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets none
Other expenses rr_OtherExpensesOverAssets 0.14%
Total annual Fund operating expenses rr_ExpensesOverAssets 0.86%
Fee waiver and/or expense reimbursement rr_FeeWaiverOrReimbursementOverAssets none
Total annual Fund operating expenses after fee waiver and/or expense reimbursement rr_NetExpensesOverAssets 0.86% [1],[2]
1 Year rr_ExpenseExampleYear01 $ 88
3 Years rr_ExpenseExampleYear03 274
5 Years rr_ExpenseExampleYear05 477
10 Years rr_ExpenseExampleYear10 1,061
1 Year rr_ExpenseExampleNoRedemptionYear01 88
3 Years rr_ExpenseExampleNoRedemptionYear03 274
5 Years rr_ExpenseExampleNoRedemptionYear05 477
10 Years rr_ExpenseExampleNoRedemptionYear10 $ 1,061
2010 rr_AnnualReturn2010 18.79%
2011 rr_AnnualReturn2011 13.03%
2012 rr_AnnualReturn2012 25.48%
2013 rr_AnnualReturn2013 56.32%
2014 rr_AnnualReturn2014 35.85%
2015 rr_AnnualReturn2015 5.36%
2016 rr_AnnualReturn2016 (14.40%)
2017 rr_AnnualReturn2017 31.40%
2018 rr_AnnualReturn2018 (3.40%)
2019 rr_AnnualReturn2019 18.58%
Highest Quarterly Return, Label rr_HighestQuarterlyReturnLabel Best Quarter:
Highest Quarterly Return, Date rr_BarChartHighestQuarterlyReturnDate Dec. 31, 2019
Highest Quarterly Return rr_BarChartHighestQuarterlyReturn 18.22%
Lowest Quarterly Return, Label rr_LowestQuarterlyReturnLabel Worst Quarter:
Lowest Quarterly Return, Date rr_BarChartLowestQuarterlyReturnDate Dec. 31, 2018
Lowest Quarterly Return rr_BarChartLowestQuarterlyReturn (20.47%)
One Year rr_AverageAnnualReturnYear01 18.58%
Five Years rr_AverageAnnualReturnYear05 6.30%
Ten Years rr_AverageAnnualReturnYear10 17.12%
Since Inception rr_AverageAnnualReturnSinceInception
PGIM Jennison Health Sciences Fund | Class R6  
Risk/Return: rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum deferred sales charge (load)(as a percentage of the lower of the original purchase price or the net asset value at redemption) rr_MaximumDeferredSalesChargeOverOther none
Maximum sales charge (load) imposed on reinvested dividends and other distributions rr_MaximumSalesChargeOnReinvestedDividendsAndDistributionsOverOther none
Redemption fee rr_RedemptionFeeOverRedemption none
Exchange fee rr_ExchangeFeeOverRedemption none
Maximum account fee (accounts under $10,000) rr_MaximumAccountFee none
Management fees rr_ManagementFeesOverAssets 0.72%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets none
Other expenses rr_OtherExpensesOverAssets 0.19%
Total annual Fund operating expenses rr_ExpensesOverAssets 0.91%
Fee waiver and/or expense reimbursement rr_FeeWaiverOrReimbursementOverAssets (0.09%)
Total annual Fund operating expenses after fee waiver and/or expense reimbursement rr_NetExpensesOverAssets 0.82% [1],[2]
1 Year rr_ExpenseExampleYear01 $ 84
3 Years rr_ExpenseExampleYear03 281
5 Years rr_ExpenseExampleYear05 495
10 Years rr_ExpenseExampleYear10 1,111
1 Year rr_ExpenseExampleNoRedemptionYear01 84
3 Years rr_ExpenseExampleNoRedemptionYear03 281
5 Years rr_ExpenseExampleNoRedemptionYear05 495
10 Years rr_ExpenseExampleNoRedemptionYear10 $ 1,111
One Year rr_AverageAnnualReturnYear01 18.63%
Five Years rr_AverageAnnualReturnYear05
Ten Years rr_AverageAnnualReturnYear10
Since Inception rr_AverageAnnualReturnSinceInception 12.00%
Inception Date rr_AverageAnnualReturnInceptionDate Jan. 27, 2016
PGIM Jennison Health Sciences Fund | Return After Taxes on Distributions | Class Z  
Risk/Return: rr_RiskReturnAbstract  
One Year rr_AverageAnnualReturnYear01 17.78%
Five Years rr_AverageAnnualReturnYear05 4.39%
Ten Years rr_AverageAnnualReturnYear10 15.12%
Since Inception rr_AverageAnnualReturnSinceInception
PGIM Jennison Health Sciences Fund | Return After Taxes on Distributions and Sale of Fund Shares | Class Z  
Risk/Return: rr_RiskReturnAbstract  
One Year rr_AverageAnnualReturnYear01 11.57%
Five Years rr_AverageAnnualReturnYear05 4.44%
Ten Years rr_AverageAnnualReturnYear10 13.96%
Since Inception rr_AverageAnnualReturnSinceInception
PGIM Jennison Health Sciences Fund | S&P 1500 Health Care Index (reflects no deduction for fees, expenses or taxes)  
Risk/Return: rr_RiskReturnAbstract  
One Year rr_AverageAnnualReturnYear01 20.87%
Five Years rr_AverageAnnualReturnYear05 10.69%
Ten Years rr_AverageAnnualReturnYear10 15.17%
Since Inception rr_AverageAnnualReturnSinceInception
PGIM Jennison Health Sciences Fund | S&P Composite 1500 Index (reflects no deduction for fees, expenses or taxes)  
Risk/Return: rr_RiskReturnAbstract  
One Year rr_AverageAnnualReturnYear01 30.90%
Five Years rr_AverageAnnualReturnYear05 11.46%
Ten Years rr_AverageAnnualReturnYear10 13.52%
Since Inception rr_AverageAnnualReturnSinceInception
[1] PGIM Investments LLC (PGIM Investments) has contractually agreed, through March 31, 2021, to limit transfer agency, shareholder servicing, sub-transfer agency, and blue sky fees, as applicable, to the extent that such fees cause the Total Annual Fund Operating Expenses to exceed 0.82% of average daily net assets for Class R6 shares. This contractual expense limitation excludes interest, brokerage, taxes (such as income and foreign withholding taxes, stamp duty and deferred tax expenses), acquired fund fees and expenses, extraordinary expenses, and certain other Fund expenses such as dividend and interest expense and broker charges on short sales. Where applicable, PGIM Investments agrees to waive management fees or shared operating expenses on any share class to the same extent that it waives such expenses on any other share class. In addition, Total Annual Fund Operating Expenses for Class R6 shares will not exceed Total Annual Fund Operating Expenses for Class Z shares. Fees and/or expenses waived and/or reimbursed by PGIM Investments may be recouped by PGIM Investments within the same fiscal year during which such waiver and/or reimbursement is made if such recoupment can be realized without exceeding the expense limit in effect at the time of the recoupment for that fiscal year. This expense limitation may not be terminated prior to March 31, 2021 without the prior approval of the Fund’s Board of Directors.
[2] The distributor has contractually agreed to limit its distribution and service (12b-1) fees to 0.50% of the average daily net assets of the Fund’s Class R shares through March 31, 2021. This waiver may not be terminated prior to March 31, 2021 without the prior approval of the Fund’s Board of Directors.
[3] Direct Transfer Agent Accounts holding under $10,000 of Class Z shares are subject to the $15 fee.